Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

Camilla Zimmermann(University Health Network), Christopher Lo(University of Toronto), Anne Rydall(University Health Network), Breffni Hannon(University of Toronto), Gary Rodin(Princess Margaret Cancer Centre), Ian F. Tannock(Princess Margaret Cancer Centre), Amit M. Oza(Ontario Institute for Cancer Research), Monika K. Krzyzanowska(Sunnybrook Health Science Centre), Nadia Swami(University Health Network), Malcolm J. Moore(University Health Network), Allan Donner(Western University), Natasha B. Leighl(Princess Margaret Cancer Centre)
The Lancet
February 18, 2014
10.1016/s0140-6736(13)62416-2
Cited by 1,792

Related Papers

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Next-generation characterization of the Cancer Cell Line Encyclopedia
|Nature|2019|3.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k